High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 143, Issue 1, 2008, Pages 54-59

  Cazin, Bruno ^a   Divine, Marine ^b   Leprêtre, Stéphane ^c   Travade, Philippe ^d   Tournilhac, Olivier ^d   Delmer, Alain ^e   Jaubert, Jérôme ^f   Feugier, Pierre ^g   Dreyfus, Brigitte ^h   Mahé, Béatrice ⁱ   Grosbois, Bernard ^j   Maloisel, Frédéric ^k   Eghbali, Houchingue ^l   Dumontet, Charles ^m   Bénichou, Jacques ⁿ   Guibon, Odile ^o   Leleu, Xavier ^a   Leporrier, Michel ^p   Maloum, Karim ^q  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Centre Hospitalier Universitaire   (France)

^c Becquerel Centre   (France)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^e HÔTEL DIEU   (France)

^f Institut du Cancer de la Loire   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h POITIERS UNIVERSITY HOSPITAL   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j RENNES UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^l INSTITUT BERGONIÉ   (France)

^m EDOUARD HERRIOT HOSPITAL   (France)

ⁿ ROUEN UNIVERSITY HOSPITAL   (France)

^o NONE   (France)

^p CAEN UNIVERSITY HOSPITAL   (France)

^q PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

more..

Author keywords

Chronic lymphocytic leukaemia; Cyclophosphamide; First line treatment; Fludarabine

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; STEROID;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOPENIA; DIARRHEA; DISEASE FREE INTERVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SPLENECTOMY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; BIOLOGICAL MARKERS; CREATININE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; VIDARABINE PHOSPHATE;

EID: 51249106396     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07309.x     Document Type: Article

References (28)

1. Bellissant, E., Benichou, J. Chastang, C. (1990) Application of the triangular test to phase II cancer clinical trials. Statistics in Medicine, 9, 907 917.
2. Bellosillo, B., Villamor, N., Colomer, D., Pons, G., Montserrat, E. Gil, J. (1999) In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood, 94, 2836 2843.
3. Boogaerts, M.A., Van Hoof, A., Catovsky, D., Kovacs, M., Montillo, M., Zinzani, P.L., Binet, J.L., Feremans, W., Marcus, R., Bosch, F., Verhoef, G. Klein, M. (2001) Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 4252 4258.
4. Borthakur, G., O'Brien, S., Wierda, W.G., Thomas, D.A., Cortes, J.E., Giles, F.J., Kantarjian, H.M., Lerner, S. Keating, M.J. (2007) Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab-incidence and predictors. British Journal Haematology, 136, 800 805.
5. Byrd, J.C., Gribben, J.G., Peterson, B.L., Grever, M.R., Lozanski, G., Lucas, D.M., Lampson, B., Larson, R.A., Caligiuri, M.A. Heerema, N.A. (2006) Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. Journal of Clinical Oncology, 24, 437 443.
6. Catovsky, D., Else, M., Richards, S. Hillmen, P. (2006) The lack of survival differences in randomised trials in CLL may be related to the effect of second line therapies. A report from the LRF CLL4 trial. Blood (ASH Annual Meeting Abstracts 108, (Abstract #304).
7. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990 4997.
8. Dearden, C., Wade, R., Else, M., Richards, S., Milligan, D., Hamblin, T. Catovsky, D. (2007) The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial. Blood (ASH Annual Meeting Abstracts 110, (Abstract #2044).
9. Eichhorst, B.F., Busch, R., Hopfinger, G., Pasold, R., Hensel, M., Steinbrecher, C., Siehl, S., Jager, U., Bergmann, M., Stilgenbauer, S., Schweighofer, C., Wendtner, C.M., Dohner, H., Brittinger, G., Emmerich, B. Hallek, M. (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 107, 885 891.
10. Eichhorst, B.F., Busch, R., Schweighofer, C., Wendtner, C.M., Emmerich, B. Hallek, M. (2007) Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. British Journal Haematology, 136, 63 72.
11. Elter, T., Borchmann, P., Schulz, H., Reiser, M., Trelle, S., Schnell, R., Jensen, M., Staib, P., Schinkothe, T., Stutzer, H., Rech, J., Gramatzki, M., Aulitzky, W., Hasan, I., Josting, A., Hallek, M. Engert, A. (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. Journal of Clinical Oncology, 23, 7024 7031.
12. Flinn, I.W., Neuberg, D.S., Grever, M.R., Dewald, G.W., Bennett, J.M., Paietta, E.M., Hussein, M.A., Appelbaum, F.R., Larson, R.A., Moore, D.F. Jr Tallman, M.S. (2007) Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology, 25, 793 798.
13. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. Stevenson, F.K. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94, 1848 1854.
14. Keating, M.J., O'Brien, S., Kantarjian, H., Plunkett, W., Estey, E., Koller, C., Beran, M. Freireich, E.J. (1993) Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood, 81, 2878 2884.
15. Keating, M.J., Flinn, I., Jain, V., Binet, J.L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B. Rai, K.R. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood, 99, 3554 3561.
16. Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M.J., Jaubert, J., Autrand, C., Divine, M., Dreyfus, B., Maloum, K., Travade, P., Dighiero, G., Binet, J.L. Chastang, C. (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood, 98, 2319 2325.
17. Lin, T., Donohue, K., Lucas, M., Byrd, J., Bengtson, E., Peterson, B. Larson, R. (2007) Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB study 10101. Blood (ASH Annual Meeting Abstracts 110, (Abstract #755).
18. Magnac, C., Sutton, L., Cazin, B., Laurent, C., Binet, J.L., Merle-Beral, H., Dighiero, G. Maloum, K. (1999) Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematology and Cell Therapy, 41, 13 18.
19. Maloum, K., Sutton, L., Baudet, S., Laurent, C., Bonnemye, P., Magnac, C. Merle-Beral, H. (2002) Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia. British Journal Haematology, 119, 970 975.
20. Montillo, M., Tedeschi, A., Miqueleiz, S., Veronese, S., Cairoli, R., Intropido, L., Ricci, F., Colosimo, A., Scarpati, B., Montagna, M., Nichelatti, M., Regazzi, M. Morra, E. (2006) Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology, 24, 2337 2342.
21. Morrison, V.A., Rai, K.R., Peterson, B.L., Kolitz, J.E., Elias, L., Appelbaum, F.R., Hines, J.D., Shepherd, L., Martell, R.E., Larson, R.A. Schiffer, C.A. (2001) Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. Journal of Clinical Oncology, 19, 3611 3621.
22. O'Brien, S.M., Kantarjian, H.M., Cortes, J., Beran, M., Koller, C.A., Giles, F.J., Lerner, S. Keating, M. (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 1414 1420.
23. Oscier, D., Orchard, J.A., Culligan, D., Cunningham, D., Johnson, S., Parker, A., Klein, M. Gieschen, H. (2001) The bioavailability of oral fludarabine phosphate is unaffected by food. The Hematology Journal, 2, 316 321.
24. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. Schiffer, C.A. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1750 1757.
25. Rossi, J.F., van Hoof, A., de Boeck, K., Johnson, S.A., Bron, D., Foussard, C., Lister, T.A., Berthou, C., Kramer, M.H., Littlewood, T.J., Marcus, R.E., Deconinck, E., Montillo, M., Guibon, O. Tollerfield, S.M. (2004) Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology, 22, 1260 1267.
26. Schweighofer, C., Ritgen, M., Eichhorst, B., Busch, R., Kneba, M., Hallek, M., Wendtner, C. the German CLL Study Group (2006) Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukemia (CLL) in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts 108.
27. Steurer, M., Pall, G., Richards, S., Schwarzer, G., Bohlius, J. Greil, R. (2006) Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews, 3, CD004270.
28. Wendtner, C.M., Ritgen, M., Schweighofer, C.D., Fingerle-Rowson, G., Campe, H., Jager, G., Eichhorst, B., Busch, R., Diem, H., Engert, A., Stilgenbauer, S., Dohner, H., Kneba, M., Emmerich, B. Hallek, M. (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia, 18, 1093 1101.